Candel Reports 88 Percent Q2 Loss Drop
Candel Therapeutics (NASDAQ:CADL), a clinical-stage biotech developing viral immunotherapies for cancer, released second-quarter results on August 14, 2025, for the period ended June 30. The most notable news was a significantly narrower net loss per share of $(0.09) (GAAP), beating analyst estimates of $(0.16). The quarter brought no revenue, as expected for a pre-commercial biotechnology company. Operating expenses increased in research and development (R&D) and general and administrative (G&A) as the company progressed toward regulatory filings. Overall, the quarter was marked by significant clinical, regulatory, and financial progress as Candel secured a longer cash runway to fund key initiatives.
Source: Analyst estimates for the quarter provided by FactSet.
Candel Therapeutics develops viral immunotherapy platforms for treating solid tumors. Its main technologies use engineered viruses—adenovirus and herpes simplex virus (HSV)—to transform the tumor environment and trigger the immune system to attack cancer.
Source Fool.com
